Dr. Gauri Krishna is a highly respected Consultant in Inherited Metabolic and Genetic Disorders with extensive international experience and over 18 years in pediatric and adult metabolic medicine. She has worked as a consultant in leading London hospitals and led multiple international research consortiums, collaborating closely with metabolic dietitians, geneticists, and multidisciplinary care teams. Renowned for her expertise in diagnosing and managing rare inherited metabolic and genetic conditions, she integrates cutting-edge research with compassionate, family-focused care. Dr. Krishna’s work in quality improvement, clinical teaching, and evidence-based therapeutics has significantly advanced pediatric metabolic care and tailored treatment strategies for complex metabolic disorders.

Educational Qualifications:

• FRCPCH
• MPhil (Medical Genetics)
• Fellowship in Clinical Genetics

Professional Experience:

• Consultant in Inherited Metabolic and Genetic Disorders (Adult & Pediatric) at Rainbow Children’s Hospital, Bengaluru
• Over 5 years of consultant experience in leading tertiary hospitals in London, UK
• Extensive experience in managing rare inherited metabolic disorders and genetic conditions in children and adults
• Served as Quality Improvement Lead and Head of Departmental Teaching in previous roles
• Principal Investigator in 4 international consortium research studies
• Sub-Principal Investigator in 4 international clinical research studies.

Awards:

• Best Oral Presentation: British Inherited Metabolic Disease Group, United Kingdom 2019
• “Best Trainee” [out of a cohort of ST4-ST8] East of England Deanery, United Kingdom. 2017
• “Best Paediatric Doctor” Cloudnine Hospital, Bengaluru, India. 2013  Highest marks in clinical membership exam in Paediatrics (MD equivalent) Royal college of Paediatrics and child health, UK. 2009
• Best thesis award University of Cambridge-Department of medical genetics, UK. 2008
• Distinction Paediatrics (MBBS) Rajiv Gandhi University of health sciences, Bengaluru, India.2003

Articles and Blogs:

• 2023 Improvement in patient outcomes following initiation of burosumab in young adults. Single centre experience: Journal of bone and mineral research (IF: 6.39) (First author) (pre-print)
• 2021 Long-term cognitive and psychosocial outcomes in adults with phenylketonuria: Journal of inherited metabolic disease (IF: 4.982) (Co-author)
• 2016 Fibrodysplasia ossificans progressiva: Seven cases of a very rare disorder with heterotopicossification: Journal of inherited metabolic disease (IF: 4.982) (5th author)
• 2015 Significance of Newborn Screening for Citrullinemia: Journal of Indian perinatology (IF: 0.33) (Corresponding Author)
• 2010 Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease: Hum Mol Genet 19(17):3413-29 (2010) (IF:6.15) (7th author).
• 2008 Huntington's disease: from pathology and genetics to potential therapies: Biochem J412(2):191-209 (2008) (IF:4.097) (7th author)
• 2008 A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin: Hum Mol Genet 17(2):170-8 (2008) (IF:6.15) (Co-author).

‍